Canada markets open in 27 minutes

Microbix Biosystems Inc. (MBX.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.4900+0.0100 (+2.08%)
At close: 03:10PM EDT
Full screen
Previous Close0.4800
Open0.4800
Bid0.4850 x 0
Ask0.4900 x 0
Day's Range0.4800 - 0.5100
52 Week Range0.4200 - 0.8700
Volume102,500
Avg. Volume34,214
Market Cap67.273M
Beta (5Y Monthly)0.19
PE Ratio (TTM)24.50
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateSept 02, 1999
1y Target EstN/A
  • GlobeNewswire

    Microbix Announces Initiation of Normal Course Issuer Bid

    Microbix to Repurchase up to 5% of its outstanding shares over 12 monthsMISSISSAUGA, Ontario, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces the initiation of a Normal Course Issuer Bid (“NCIB”) program for the repurchase and cancellation of outstanding common shares. Specifically, the NCIB enables Microbix to repurchase up to 6,949,568 Common Shares ("Shares"), that being approxima

  • GlobeNewswire

    Microbix Presenting at Muskoka Capital Conference

    Meetings with Growth-Oriented Investors, September 23-25, 2022MISSISSAUGA, Ontario, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting to investors at the Muskoka Capital Conference, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Rosseau Muskoka, in Minett, Ontario, September 23-25, 2022. Microbix’s CEO, Cameron Groome and COO,

  • GlobeNewswire

    Microbix Reports Results for Q3 Fiscal 2022

    Q3 Sales of $5.0 million, Q3 Net Earnings of $0.6 millionMISSISSAUGA, Ontario, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and year-to-date fiscal 2022 ended June 30, 2022 (“Q3” and “YTD”), with strong sales and continued positive net earnings, plus ongoing progress upon its strategic goal of increasing its capacity for medical devices production to the